Company Profiles

driven by the PitchBook Platform

ARMO BioSciences

Description

Developer of immunotherapeutics. The company is a clinical-stage enterprise developing immunotherapies focused on multiple, difficult-to-treat oncology indications. Its lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. It plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors.

2012

Founded

PRIVATE

Status

11-50

Employees

Series C

Latest Deal Type

$50M

Latest Deal Amount

$100M

Total Amount Raised

Description

Developer of immunotherapeutics. The company is a clinical-stage enterprise developing immunotherapies focused on multiple, difficult-to-treat oncology indications. Its lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. It plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors.

Website:

www.armobio.com

Formerly Known As

Targenics

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery
Pharmaceuticals

Primary Office

575 Chesapeake Drive Redwood City, CA 94063United States
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore ARMO BioSciences's full profile, request a free trial.

ARMO BioSciences Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

ARMO BioSciences Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

ARMO BioSciences Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
CelgeneCorporationMinority000 0000000 0000
Clough Capital PartnersMutual FundMinority000 0000000 0000
Duff Ackerman & GoodrichPE/BuyoutMinority000 0000000 0000
GVCorporate Venture CapitalMinority000 0000000 0000
HBM Healthcare InvestmentsVenture CapitalMinority000 0000000 0000
Celgene Corporation
Clough Capital Partners Mutual Fund
Duff Ackerman & Goodrich PE/Buyout
GV Corporate Venture Capital
HBM Healthcare Investments Venture Capital

ARMO BioSciences Executive Team (4)

NameTitleBoard
Seat
Contact
Info
Martin Oft MDCo-Founder & Vice President, Pre-Clinical & Clinical Development
Scott Ogg Ph.DVice President, Corporate Development & Operations
Gail Brown MDChief Medical Officer
Peter Van Vlasselaer Ph.DChief Executive Officer, Co-Founder, Board Member & President
Martin Oft MD Co-Founder & Vice President, Pre-Clinical & Clinical Development
Scott Ogg Ph.D Vice President, Corporate Development & Operations
Gail Brown MD Chief Medical Officer
Peter Van Vlasselaer Ph.D Chief Executive Officer, Co-Founder, Board Member & President

ARMO BioSciences Board Members (3)

NameRepresentingRoleSinceContact
Info
Beth Seidenberg MDKleiner Perkins Caufield & ByersPartner000 0000
Carl Gordon Ph.DOrbiMedFounding Partner & Co-Head of Global Private Equity000 0000
Peter Van Vlasselaer Ph.DSelfChief Executive Officer, Co-Founder, Board Member & President000 0000
Beth Seidenberg MD Partner Kleiner Perkins Caufield & Byers
Carl Gordon Ph.D Founding Partner & Co-Head of Global Private Equity OrbiMed
Peter Van Vlasselaer Ph.D Chief Executive Officer, Co-Founder, Board Member & President Self
Request full access to PitchBook